TELO

Telomir Pharmaceuticals, Inc. (TELO) - Q1 2025 10-Q Summary

Business Context and Reporting Period

Telomir Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing Telomir-1, an oral small molecule designed to regulate metal ions (iron, copper, zinc) to combat oxidative stress and extend telomere caps. The company targets age-related conditions such as Progeria, Wilson's disease, and Alzheimer's, as well as viral infections. This report covers the quarterly period ended March 31, 2025. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $4.1 million compared to Q1 2024. This improvement was primarily driven by the absence of $4.3 million in interest expense related to the amortization of debt issuance costs on a related party line of credit that was closed in the prior year.
• Expense Shifts: General and Administrative (G&A) expenses increased significantly to $1.85 million from $0.74 million, largely due to $1.38 million in stock-based compensation. Conversely, Research and Development (R&D) expenses decreased to $0.34 million from $0.80 million as the company focused on conserving cash.
• Liquidity Decline: Cash balances dropped by approximately $863,000 during the quarter, reducing total cash from $1.27 million to $0.40 million. The company moved from a positive stockholders' equity position of $0.64 million to a deficit of $0.16 million.
• Related Party Costs: Related party travel costs, which were $0.37 million in Q1 2024, were $0 in Q1 2025 following the termination of an airplane lease agreement.

Outlook, Risks, and Management Commentary

• Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With only $0.4 million in cash and a burn rate of approximately $0.9 million per quarter, the company expects its current resources to be sufficient only through the second quarter of 2025.
• Funding Needs: The company is actively seeking additional debt or equity financing to fund operations and clinical trials. There is no assurance that such funding will be available on commercially reasonable terms.
• Subsequent Events: Between April 1 and May 13, 2025, the company sold 18,300 shares under its At-The-Market (ATM) agreement for net proceeds of approximately $47,769. Additionally, an Executive Incentive Compensation Plan was adopted for the CEO, tied to clinical milestones, partnerships, and capital raises.
• Scientific Progress: Recent preclinical data announced in Q1 2025 indicated Telomir-1's ability to reverse copper-induced oxidative stress, reduce tumor size in prostate cancer models, and restore lifespan in progeria models.
• Risks: Key risks include the inability to secure additional funding, failure to achieve regulatory approval, and the inherent uncertainties of preclinical and clinical development.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to raise capital immediately, as current cash ($402,999) is insufficient to fund operations beyond Q2 2025.
• Stock-Based Compensation: Review the $1.38 million stock-based compensation expense included in G&A, which significantly impacts the net loss but is a non-cash item.
• Related Party Transactions: Confirm the status of the $93,432 due to related parties and the terms of the unused $5 million Starwood Trust line of credit.
• ATM Utilization: Monitor the utilization of the $100 million shelf registration and ATM agreement, noting only minimal sales ($47,769) occurred in the subsequent period.
• Going Concern Status: Assess the likelihood of a potential equity dilution or debt restructuring given the working capital deficit and accumulated deficit of $32.8 million.